Home › Compare › APLUF vs ABBV
APLUF yields 16.67% · ABBV yields 3.06%● Live data
📍 APLUF pulled ahead of the other in Year 1
Combined, APLUF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of APLUF + ABBV for your $10,000?
Applus Services, S.A., together with its subsidiaries, provides testing, inspection, and certification services. It operates through four segments: Applus+ Energy & lndustry, Applus+ Laboratories, Applus+ Automotive, and Applus+ IDIADA. The Applus+ Energy & lndustry segment offers non-destructive testing, quality control, and accreditation services, as well as project management, supplier inspection, facility inspection, and asset certification and integrity services. This segment also provides qualified staff recruitment and hiring services for the oil and gas, aircraft, energy, mining, telecommunications, and construction industries. The Applus+ Laboratories segment offers a range of laboratory testing, system certification, and product development services across various industries and electronic payment systems, including aerospace and industrial sectors. The Applus+ Automotive segment provides mandatory vehicle roadworthiness testing services, as well as verifies vehicles' compliance with safety and emissions regulations in force in various countries. The Applus+ IDIADA segment offers design, engineering, testing, and certification services primarily to car manufacturers. It operates in Spain, rest of Europe, the United States, Canada, the Asia Pacific, the Middle East, Africa, and Latin America. The company was formerly known as Applus Technologies Holding, S.L. and changed its name to Applus Services, S.A. in March 2014. Applus Services, S.A. was founded in 1996 and is headquartered in Madrid, Spain.
Full APLUF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.